ArticleCureus2025
Recurrent Aggressive Angiomyxoma That Responded to the Gonadotropin-Releasing Hormone (GnRH) Antagonist Relugolix.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Vulvar Aggressive Angiomyxoma in a Postmenopausal Woman: Diagnostic Pitfalls and Surgical Implications-A Case Report.Case reports in obstetrics and gynecology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aggressive angiomyxoma (AAM) is a rare benign mesenchymal tumor occurring in the vulva, vagina, and pelvis; however, it is difficult to treat because it often recurs locally. Since AAM expresses the estrogen receptor (ER) and progesterone receptor (PgR), various hormone therapies have been reportedly effective. Regardless, the efficacy of gonadotropin-releasing hormone (GnRH) antagonists has not yet been reported. We encountered a case of relapsed AAM in which the GnRH antagonist relugolix was highly effective. Although the patient initially underwent surgical resection for the AAM, recurrence occurred 11 months postoperatively. Since the immunohistochemical expression of ER and PgR was positive, relugolix (40 mg/day) was orally administered daily for six months, resulting in significant tumor regression (8.7 cm to 4.6 cm). This is the first report of successful GnRH antagonist treatment for AAM. Although AAM may be difficult to treat, GnRH antagonists are promising candidates for hormone therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.